A study by Jin et al. [29] found that treating three human lung cancer cell lines (A549, H1650 and H460) with 20 μM EGCG inhibited anchorage-independent growth of all three cell lines via upregulation of p53 expression, increased phosphorylation of tumour protein p53 (TP53) at anti-phospho-p53 (Ser15) and anti-phospho-p53 (Ser20) and enhancement of its transcriptional activity, as well as inhibition of mouse double minute 2 (MDM2)-mediated TP53 ubiquitination. This evidence concerns the gene TP53 and lung cancer.